Invex Therapeutics (ASX:IXC) reports setbacks in enrolment for IIH EVOLVE phase III trial
Invex Therapeutics (IXC) has reported lower-than-expected enrolments for its intracranial hypertension (IIH)…
Invex Therapeutics Ltd (ASX:IXC)
About Invex Therapeutics Ltd
Key Information
IXC In the News
ASX Announcements
| Date | Announcement | File | Views |
|---|---|---|---|
| 19/04/2024 | Details of Auditor Appointment/Resignation | 176.2KB | 203 |
| 12/04/2024 | Price Sensitive PS Quarterly Activities/Appendix 4C Cash Flow Report | 480.45KB | 229 |
| 09/04/2024 | Change of Director's Interest Notice | 218.02KB | 168 |
| 08/04/2024 | Notification of cessation of securities - IXC | 12.68KB | 158 |
| 03/04/2024 | Change of Director's Interest Notice | 219.69KB | 207 |
| 22/03/2024 | Amendment to Appendix 3A.4 | 170.57KB | 183 |
| 20/03/2024 | Price Sensitive PS ATO Class Ruling Return of Capital | 349.06KB | 317 |
| 05/03/2024 | Update on R&D Tax Rebate from UK Government | 184.22KB | 556 |